Form 4: Daxor Corp Director Granted Stock Options

Daxor Corp director Edward Feuer has been granted stock options contingent on SEC approval of an amended incentive plan.

Summary

• Edward Feuer, a Director at Daxor Corp (DXR), was granted 2,500 stock options on June 23, 2026.
• The grant is subject to the SEC's approval to amend the Daxor Corporation 2020 Incentive Compensation Plan.
• The stock options have an exercise price of $10.14.
• Vesting will occur in three installments: 833 options on June 23, 2026, 883 on June 23, 2027, and 834 on June 23, 2028.
• The options expire on June 23, 2031.
• Following the grant, Feuer beneficially owns 2,500 shares directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it details a standard compensation grant for a director that is contingent on regulatory approval, with no immediate financial impact or significant strategic shift indicated.

Positives

• Director Edward Feuer has been granted stock options, indicating potential future value tied to the company's performance.
• The grant is structured with staggered vesting over three years, aligning the director's incentives with long-term company growth.

Negatives

• The stock option grant is contingent on SEC approval of an amendment to the company's incentive compensation plan, introducing regulatory uncertainty.

Risks

• The primary risk is the potential disapproval by the SEC of the amended incentive compensation plan, which would invalidate the stock option grant.
• The value of the stock options is subject to market fluctuations and the company's future stock price performance.

Future Outlook

The future outlook for the stock options is dependent on SEC approval of the amended incentive plan and the future performance of Daxor Corp's stock.

Industry Context

StockSavvy.ai notes that the granting of stock options to directors is a common practice in the biotechnology and healthcare sectors, aligning executive interests with shareholder value, though the reliance on SEC approval for the plan amendment adds a layer of regulatory scrutiny typical for companies operating under strict compliance frameworks.

Corporate Governance

Related Party Transactions

• Grant of 2,500 stock options to Director Edward Feuer with an exercise price of $10.14, vesting over three years and expiring in 2031, contingent on SEC approval of an amended incentive plan.

Stakeholder Impact

• Shareholders: The grant aligns director incentives with long-term stock performance, but the ultimate value is contingent on company success and regulatory approval.
• Employees: The amendment to the incentive plan, if approved, could set precedents for future employee compensation structures.
• Management: The grant reinforces the compensation structure for directors.

Next Steps

• Await SEC approval for the amendment to the Daxor Corporation 2020 Incentive Compensation Plan.
• Monitor the vesting schedule and expiration of the granted stock options.

Key Dates

Keywords

stock options, insider trading, SEC filing, Daxor Corp, DXR, incentive plan, director compensation, Form 4